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In most countries with market economies, the flow of
pharmaceuticals is dominated by the major drug
producers and their agents, whose main interest is
profit [Lazio 1977; Muller 1982]. With few exceptions,
the regulatory control of health authorities is very
weak and, in Third World countries, is often almost
non-existent. Doctors are under strong pressure from
the industry's promotional activities, and they are
bombarded by printed advertising material and visits
by drug-company representatives [Galice 1974;
Yudkin 1978; Medawar 1979; Brudon 1981; Melrose
1982]; in some Third World countries, representatives
are as numerous as one to every three doctors
[Silverman 1976].
In this situation, the market is flooded by thousands of
pharmaceutical products, many of which are
ineffective, unnecessary, or even harmful [de Brabant
1979; Wolfe et al 1981; November 1981; Health Action
International 1982]. The actual number of useful drug
substances does not exceed a few hundred, and this
unnecessary profusion of pharmaceuticals is the result
of:
- brand-named drug combinations, which in most
cases have no therapeutic advantage (they may
even be quite irrational) and are more expensive
than the individual drugs marketed separately;
- imitative drugs, which result from minor changes
to known compounds and which generally have no
substantial advantages over the existing drugs,
being introduced only to bypass patent protection;
- drugs of unproven efficacy, marketed singly or in
combination;
- multiplicity of brands for the same drug substance;
- fancy formulations of any of the above, with
unproven advantages and usually exorbitant prices.
[UNCTAD 1980; Yudkin 1980; Marzagão and Segall
1983]
In pre-independent Mozambique, these were among
the many problems that characterised the pharma-
ceutical sector.
In 1974, the last colonial year, the government drug
budget was about US $1 mn for a population of some
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Pharmaceutical Chaos during the Colonial
Period
Before independence in June 1975, Mozambique's
pharmaceutical market was flooded by some 13,000
products, which «sere promoted by drug-company
representatives, of whom there were about one for
every five doctors. Promotion was targeted especially
on the 500 or so doctors then working in the country,
most of them in private practice at least part time. As
in other Third World countries, the doctors and
medical facilities were greatly concentrated in the
urban areas. The settler population - a colonial
bourgeoisie, most of whom also lived in the towns
constituted the main drug market. As a well-to-do
class they could afford to pay for pharmaceuticals,
and some of them were also covered by health
insurance schemes which included drug costs. The
distribution of retail pharmacies was also an
indication of the discriminatory nature of medical
services. Of the 80 pharmacies then existing in the
country, 45 were in the capital city and all the others
were in the towns where the settlers lived. The mass of
the population had little access to medical and
pharmacy facilities, and especially in the rural areas,
the supply and marketing of drugs was very irregular,
poorly planned and uncontrolled.
There was no pharmaceutical industry in the country
and all drugs were imported in the finished state. The
six main supplying countries were Portugal, Switzer-
land, West Germany, South Africa, France and the
United Kingdom. The manufacturers included the
major pharmaceutical transnational corporations
(TNCs), and some drugs were imported as virtual
monopolies of certain firms. Over-invoicing of drug
imports was a common practice, which created very
high prices and drained the country's scarce foreign
exchange. During the last few years of the colonial
period, all local subsidiaries of the TNCs showed
financial deficits, which were the result of transfer-
pricing manoeuvres to channel hidden profits to the
parent companies abroad.
9 mn, an average expenditure of only US $0.11 per
person.' The government had little bargaining power
in relation to the TNCs for reducing the cost of drugs,
since it did not have a central procurement agency;
indeed, it had almost no regulatory role in the import,
marketing and use of pharmaceuticals. Importation
was in the hands of private agencies representing
various manufacturers or specific TNCs. Import
licences were required as a formality, but there was no
effective import control. (The only drug ever refused
admission to the market was thalidomide.) There was
in fact a financial incentive for importers and retailers
to deal in expensive products, since their mark-up was
calculated as a fixed percentage of the price.
Medicines were sold to the public with little control,
and even drugs theoretically requiring a prescription
could be obtained easily over the counter in a retail
pharmacy or, in the rural areas, even in a general store.
In the absence of proper medical care, especially for
the mass of poor people, a great deal of uninformed
self-medication occurred, as well as over-the-counter
medication by pharmacists or even by pharmacists'
assistants (who were in most cases very poorly
qualified). Only drugs of addiction were controlled.
The lack of pharmaceutical regulation also allowed
the occurrence of promotional malpractices, which
were particularly common for the more expensive
products. As in many other Third World countries
[Medawar 1979, 1980a,b;Brudon 1981; Medawar and
Freese 1982; Muller 1982; Silverman et al 1982], side-
effects, contraindications and warnings were often
minimised or omitted, while the range of indications
was frequently exaggerated.
A Health Care Revolution
One month after independence, in the context of far-
reaching political, social and economic changes, the
health care sector was nationalised and private
medicine was abolished. In 1977 a comprehensive and
integrated national health service (NHS) was set up.
Preventive care and inpatient treatment became free of
charge. Only ambulatory curative consultations were
subject to the payment of a token registration fee,
which was intended to discourage people from seeking
attention when they did not really need it. Even for
outpatient treatment, basic drugs for treating the most
common problems were free. Families earning less
than the equivalent of US$125 per month (which
applied to more than 90 per cent of the population)
had to pay only S per cent of the cost of other drugs
available through the health service.
This is according to the official colonial figures. Post-independence
census data indicate that the population in 1974 must have been
greater than the colonial estimate, so theper capita drug expenditure
was actually less.
Some key features of a new health policy were defined
[FRELIMO 1977; Ministério da Saúde 1978a], with
two major characteristics. First, priority was given to
prevention and, within this strategy, primary
prevention was given priority over secondary and
'tertiary' prevention. Secondly, the primary health
care approach was adopted - before the Alma Ata
conference2 - as national policy. This included the
following priority programme components: environ-
mental hygiene, health and nutrition education,
quality control of water and food, mother and child
health (including family planning), school health,
occupational health, oral health, and mental health.
Emphasis was placed on extending health care
coverage in the rural areas by means of newly-defined
health teams, which included medical assistants, rural
medical aides and preventive health cadres. Com-
munity participation in health promotion was
fundamental to the approach [Martins et al 1977] and
was organised utilising the new social structures that
were being created; in the rural areas these included
above all the 'communal villages' where peasants,
living and working together, selected some of their
members for training as village health workers.
The Main Principles of the New
Pharmaceutical Policy
In setting up a new pharmaceutical policy, five main
principles appeared paramount:
- Pharmaceutical policy should be part of the overall
health policy aimed at serving the mass of the
population without discrimination.
- The new NHS, as the sole authority in the health
sector, should develop adequate structures for the
management of pharmaceuticals, including their
regulation, procurement, production, promotion,
distribution, and utilisation.
- The new pharmaceutical regulatory system should
end the flow of ineffective, harmful and unnecessary
products onto the market, and so create the
conditions for the proper utilisation of useful
drugs, thereby improving the quality of medical
practice in the interest of public health.
The scarce resources available for pharmaceuticals
should be used economically, and the drug
management mechanisms should be capable of
obtaining as many appropriate drugs as possible
for a given amount of money, so that the people
could have the right product available at the right
place at the right time.
- The new pharmaceutical policy should reinforce
national economic independence.
2 The WHO/UNICEF international conference on primary health
care held at Alma Ata, USSR, in September 1978.
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Early Steps and Institutional Changes
Guided by these principles, several major measures
were taken immediately after independence. First,
within a reorganised Ministry of Health, a new
Pharmaceutical Service was created in August 1975
directly subordinate to the Minister of Health. Then in
September 1975, a Therapeutics and Pharmaceuticals
Expert Committee (CTTF)3 was created with
technical advisory functions. Its membership was
drawn from clinicians, pharmacologists and pharma-
cists, and it included officials of the Ministry's
Pharmaceutical Service. The tasks of this committee
were to:
- define the pharmaceutical products which may
circulate in the country;
- revise and update the national formulary for health
service use;
- advise on product selection in the procurement of
pharmaceuticals;
- disseminate scientific information on the use of
drugs and the choice of therapeutic agents;
- advise on all aspects of pharmaceutical policy.
In the same month a Central Agency for Medicines
and Medical Supplies was established under the
authority of the Pharmaceutical Service to centralise
the procurement and distribution of all drugs and
supplies in the NHS. Construction of new premises
was started in the city of Beira, a port situated
centrally in the country. (In subsequent years, some
provincial and district medical stores were created,
and strong efforts were made to develop their
functional capacity and their coordination with the
central agency.)
A first reduction in the number of pharmaceutical
products on the market was effected by means of an
unofficial 'gentlemen's agreement' between the
Ministry of Health and the private drug agencies and
representatives. A new law was passed in October 1975
obliging all importers and distributors to re-register
the pharmaceutical products that they wanted on the
market. For each product registered they were obliged
to pay a fee, which was calculated in such a way as to
discourage the registration of products with low
demand. The drug firms were informed that the
Ministry of Health wished to see as few products as
possible on the market, but the law did not oblige the
firms to reduce the number of preparations; they could
register whatever drugs they wanted. Any compliance
with the Ministry's wishes would be entirely voluntary
- an arrangement that the companies very much
wanted to preserve. It turned out that the firms
reduced the number of products on the market from
Comissâo Técnica de Terapêutica e Farmácia.
The number of products on the market was reduced further in 1980
to about 1,200.
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about 13,000 to some 2,600e (from the commercial
standpoint this in fact rationalised the companies'
operations and allowed them to concentrate their
efforts on a smaller number of better-selling items).
This important result was thus achieved simply -
without conflict with the pharmaceutical industry -
within a few months of independence, before the
expert CTTF had even got started. The system also
allowed the revision of the disorganised colonial
system of drug registration and the updating of
product records, and it earned the government about
US $70,000 in registration fees. When attempting to
achieve radical transformation, it is important to
know that progress takes place in stages and to judge
how to set the pace of change.
A New National Formulary
As indicated earlier, the major thrust of the
pharmaceutical policy was to improve the quality of
medical practice. To attain that goal it was essential to
reduce the number of available drugs by eliminating
inappropriate products and to impede promotional
misinformation. This also had its economic aspect,
above all to prevent the waste of scarce resources on
unnecessarily expensive branded preparations.
Attention to the quality of medical care was an urgent
necessity in the early post-independence years. There
had been a mass exodus of medical personnel, and at
independence the country was left with just 85 doctors,
of whom only 32 were Mozambicans. It was foreseen
that most of the remaining Portuguese practitioners
would also leave in subsequent years (as in fact
transpired), and that doctors would come from very
many other countries to fill the breach. In fact by
December 1979 there was a total of 317 medical
practitioners from more than 40 countries (by then 101
ofthe doctors were nationals). The question was: how
would doctors from all these different countries -
used to drugs designated by the particular trade names
of their homelands - be able to relate to each other
and to the pharmaceutical situation in Mozambique?
How would it be possible to achieve some uniformity
in prescribing out of this medical anarchy?
It was clear already in 1975 that a new national
formulary (NF) should be compiled as soon as
possible for use in the developing health service. This
formulary would:
- include all products necessary for the prevention,
diagnosis and treatment of all diseases found in the
country, and include also second- and third-line
drugs, since the aim was (and should be seen to be)
medicine of the highest quality;5
- list drugs by international nonproprietary names
and abolish trade names in the health service,
including for prescription;6
- be used as the basis for all aspects of drug
management.
Guidelines for product selection were drawn up. They
included the criteria of efficacy and safety (the
benefit/risk ratio), cost and quality. In making a
selection these criteria should be weighed up one
against the other, and a balanced judgement made.
Drug combinations were to be chosen only on those
few occasions when there was a recognised therapeutic
advantage, and fancy formulations of unproven value,
especially when expensive, were to be excluded.
With these terms of reference, the CTTF started work
and in December 1976 - about 10 months before the
WHO expert committee on the selection of essential
drugs presented its first report [WHO 1977)the NF
was approved. It was published in January of the
following year [Ministério da Saúde 1977a1, and at the
same time prescription by generic name became
compulsory in the health service. The NF listed 640
items, comprising 430 therapeutic substances in
different dosage forms and strength, 20 diagnostic
agents and 14 dressings. The NF is subject to revisions
and a second version has been published [Ministério
da Saúde 1980]. It contains only 502 items, comprising
343 therapeutic substances in different dosage forms
and strengths, 19 diagnostic agents and 12 dressings.
Limited Formularies and Lists
In a country like Mozambique, where not only doctors
but also lesser-trained health workers prescribe
medicines, it is extremely important to define which
This concept of an all-embracing national formulary differs from
the restricted sense in which 'essential drugs lists' are sometimes
understood. For example, though drugs with serious side-effects
would not be included when less toxic alternatives existed, they
would be included if they were the only weapons against certain
diseases, including rare ones.
As a compromise with public demand, pharmaceuticals for sale
over the counter in retail pharmacies still include some popular
brand-name preparations, which are mostly placebos.
drugs the latter cadres may use. Therefore, limited
formularies for medical assistants, medical aides and
other categories of health workers have been
published and updated [Ministério da Saúde 1977b,
1981a,bI.
Another measure to help make basic pharmaceuticals
available to the mass of the rural population was the
definition by the Ministry of Health in 1977 of those
drugs which could be sold without prescription by
general stores in areas where there were no retail
pharmacies.7 The updated list of 1981 contained 56
generic products.
Drug Information, Therapeutic Guidelines and
Compliance in Prescribing
Although the establishment of an effective NF is the
most important measure for rationalising prescribing
practices, it is not a panacea for solving all therapeutic
'ills'. Drugs can still be used incorrectly. For example,
items included in the NF for the treatment of rare
diseases or for highly specific indications can be
misused for other purposes, and products included as
second- or third-line drugs can be prescribed as first-
line therapy, with negative medical and economic
consequences. Thus one of the main tasks became to
educate doctors, other health care personnel (including
pharmacists and pharmacy assistants) and the general
public, on the purposes and use of the NF, and to
provide information on rational therapeutic policies.
NOIIAS SOBRE CUIDADOS CON
U RECÉUNASCUIU
This liberalisation of the sale of non-prescription drugs was
accompanied by a more strict control on the sale of prescription
drugs.
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The few medical representatives still remaining in the
country at that time continued to pressurise doctors
and other health workers to prescribe drugs that were
not in the NF or to prescribe by trade name, under the
pretext that only the branded products of their
companies were of good quality. However, the
adoption of the NF and of compulsory generic-name
prescribing, as well as other measures to control
pharmaceutical imports, soon provoked the virtual
disappearance of the pharmaceutical industry's
promotional activities, as these became no longer
worth while economically.
The main task was thus to replace the previous system
of commercial misinformation with one that would
show prescribers that better quality medicine would
result from the acceptance of discipline in prophylactic,
diagnostic and therapeutic practice. Especially during
1977 and 1978, soon after the publication of the NF, a
great deal of effort was put into the production and
distribution of printed material, and into other
educational activities, to provide unbiased, scienti-
fically-sound, pharmacological and therapeutic infor-
mation.
In the months following the appearance of the NF, the
first official strategies for the control of four major
endemic diseases (malaria, leprosy, tuberculosis and
sleeping sickness) were published, and this was
followed by later publications on the control and
management of schistosomiasis, intestinal parasitosis,
and diarrhoea [Ministério da Saúde l977c,d,e, 1978b,
1979]. These strategies were concluded only after wide
professional soundings and much discussion. While
they included the setting of norms for the prevention,
diagnosis and treatment of individual cases, their main
approach was prevention and control through public
health measures.
At the same time, suggested and 'compulsory'
therapeutic schemes were published for use in routine
clinical situations. The 'compulsory' character of
some of the more important norms was actually
theoretical, since it was impossible to monitor their
implementation, but this official-sounding designation
was intended to add to their persuasiveness.
Information was also provided on the relative costs of
drugs - virtually unknown to most health workers
- and advice was given on how to prescribe cost-
effectively [CTTF 1978; Barker et al 1980].
In 1978, it was decided that much of this
pharmaceutical information should be compiled in a
single Therapeutic Guide. This would be in two
volumes, the first giving information on each of the
products in the NF (pharmacological properties,
indications, contraindications, dosage, side-effects,
warnings, etc), and the second giving therapeutic
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guidelines for managing the most frequent clinical
situations in the country. After laborious work by the
CTTF, the Guide was finally published [Ministério da
Saúde 198 Ic], and it represents a major step towards
establishing scientific and rational therapeutic practice
in Mozambique.
Informational material was not only published, it was
also widely distributed, explained and discussed.
Practical compliance with the NF and the therapeutic
schemes has naturally presented problems, especially
in the early period, but it has improved with time,
actually more rapidly than was expected. The few
Mozambican doctors trained during the colonial
period were committed to the NF - in the compiling
of which many had participated - and new graduates
were already educated in the NF system. Some
expatriate doctors had difficulties in adjustment in the
beginning, but many came to find that the simplified
prescribing rules were a welcome relief from the
pharmaceutical anarchy in their own countries. They
realised that the rules, which included among other
things a reduction in the use of placebos, actually
improved the quality of their medical practice.
In 1981, four years after the publication of the NF, an
assessment of health worker compliance was made
[Patel et al 1981]. A study of over 4,000 prescriptions
from several health units of different types in Maputo
City and province showed that 83 per cent of all
prescriptions were in accordance with NF prescribing
rules and only 5 per cent employed trade names.
Compliance was lowest in the casualty department of
Maputo Central Hospital, where there are health
workers from various countries and where there is
little direct supervision. The average number of drugs
per prescription was 2.3, which compares very
favourably with reports from other countries [Barnett
et al 1980; Maitai and Watkins 1980; Victora et al
1982] and with the previous practice of polypharmacy8
in Mozambique.






Centralisation of Pharmaceutical Procurement
It was clear from the beginning that substantial
savings in foreign exchange could be made by
reorganising the drug supply system. As stated earlier,
procurement for the NHS had already been
centralised in a single agency since 1975, but
importation remained exclusively in the hands of the
private firms, which were also supplying the retail
sector. In 1976, the Ministry of Health began to put
out its drug orders for competitive tender on the basis
of generic names. The 27 local private importers
participated in the tender system, but at the same time
the government was also beginning to acquire drugs
directly through international tenders. In order to
expand this latter activity, a state corporation
(MEDIMOC EE) for the import and export of
pharmaceuticals, and medical supplies and equipment,
was created in 1977 by the merging of five private
import companies which had been abandoned by their
foreign owners. One of the tasks of the new state
enterprise was to increase competition in the tender
system by inviting worldwide bids, including bids
from producers in socialist countries and in Third
World countries like India, Brazil and Cuba.
MEDIMOC submitted its first tenders to the Ministry
of Health in 1978, competing with the remaining
private importers. By the end of that year it was
already handling about 60 per cent by value of the
NHS drug tenders {Marzagao and Segall 19831 and
had a fair management capability, including in market
intelligence. An investigation of the private importers'
accounts showed that the illegal export of foreign
exchange through over-invoicing and other means was
still a widespread occurrence. The trading licences of
the companies were therefore withdrawn and
MEDIMOC was given a monopoly of pharmaceutical
imports, for both the NHS and the retail pharmacy
sector.
The expert CTTF advises MEDIMOC on product
selection. Since the introduction of competitive
international tendering, the sources of imported drugs
have diversified greatly and average prices have
declined despite inflationary price increases in the
international pharmaceutical market. A comprehen-
sive study of drug imports has demonstrated that in
1979 the drug tender system gave rise to savings of the
order of 41 per cent [Pereira and Velasquez in press].
Since 1980, the purchase of pharmaceuticals in small
package units for the retail trade has also been effected
through international tender. Average prices for these
items have also decreased, and the price reductions
have been passed on automatically to the consumer.
This is an important area where savings can be made.
In 1979, the acquisition of these small packages
represented about one-fifth of the volume of
pharmaceuticals imported but about a half of the
country's drug bill in foreign exchange [Pereira and
Velasquez in press].
The Retail Pharmacy Sector
The owners and/or managing pharmacists of many
retail pharmacies left Mozambique around the time of
independence. Some shops closed and others were left
without proper supervision. Although it was not the
general policy of the government to take over retail
commerce, it had to intervene in this situation.
Closure of some of the pharmacies in central urban
areas was not such a problem, but closure of the only
pharmacy outlets in underserved areas created great
hardship. There was also a need to reorganise the
whole retail network, since the pen-urban and rural
areas were virtually deprived of a pharmacy service.
In 1977 a state corporation (FARMAC EE)
concerned with the retail sale of pharmaceuticals and
medical supplies was set up. It was to be responsible
for supervising and developing the retail network as a
whole, taking over and reopening abandoned
pharmacies, and representing the interests of the state
in those pharmacies in which it acquired a supporting
share. Private commercial interests with the legally-
required technical capacity to manage pharmacies
were encouraged to continue and expand their
businesses.
Quality Control
At independence Mozambique did not have a quality
control laboratory, and the need to establish
mechanisms to assure the quality of imported drugs
was realised from the beginning. This was a particular
consideration when cheaper generic products were
being purchased, since the Ministry of Health, the
medical professionals, and the general public alike,
wished to be certain of their quality.
In 1979, the country began to participate in the WHO
Certification Scheme on the Quality of Pharmaceutical
Products moving in International Commerce, and a
clause on certification of quality was included in the
tender rules. Cooperating governments and quality
control laboratories abroad have also helped (free of
charge) with the analysis of samples of drugs about
which there was suspicion. Quality control tests have
now started in Mozambique, at first using the existing
facilities in the pharmacology laboratory of the
medical school, and more recently in the country's
new Water and Food Hygiene Laboratory of the
Ministry of Health. At the present time, randomly-
selected samples of imported drugs are checked
regularly either in Mozambique or abroad, and the
quality of products is maintained. Plans are under way
to establish a national quality control laboratory.
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Local Production
The Third Congress of FRELIMO set the objective of
creating a national pharmaceutical industry [FRE-
LIMO 1977]. It was planned to start with a product
formulation plant and subsequently to progress
towards more complex stages of drug production.
Careful preparatory studies have been made and,
although implementation has not been as rapid as was
first hoped, the development process is under way. A
small plant for the production and packaging of oral
rehydration salts in sufficient volume to cover the
needs of the country has just started operation.
Increasing Volume and Improved Distribution
of Pharmaceuticals
Table 1 shows the greatly increased drug expenditure
by the government over the years since independence.
This increase is even more significant in volume terms,
given the general decrease in drug import prices
achieved by the new central procurement system.
Table I
Government pharmaceutical budget*
* Calculations made using data from several official sources.
Parallel with the rising volume of pharmaceuticals has
been an attempt to improve their distribution.
Allocations to provinces are now made on the
combined criteria of population and the availability
and level of health care facilities. Improved drug
distribution is illustrated by the fact that the
proportion of government pharmaceutical expenditure
allocated to Maputo Central Hospital, with some 12
per cent of the country's hospital beds, has fallen from
about 50 per cent during the colonial period to about
10 per cent since 1978. However, a more rational,
equitable and efficient distribution system is still
needed.
Problems, Achievements and Conclusions
Many problems still exist. Although there have been
large increases in the pharmaceutical budget and
reductions in the prices of drug imports, shortage of
foreign exchange (as in many Third World countries)
68
is a persisting obstacle to making essential drugs
available to the whole population, especially in the
rural areas. Despite improvements in drug manage-
ment difficulties still continue, particularly in relation
to stock handling at different levels, transport, storage
and distribution; drugs intended for the provinces and
the rural areas may arrive only after considerable
delays. As mentioned, pharmaceutical production is
much behind schedule. Also, despite all the
educational efforts already made, the flow of
therapeutic information is still below the level it
should be; and drug legislation is not yet complete.
However, very important achievements have been
attained in the few years since independence. In
Mozambique the pharmaceutical sector is rid of
ineffective, unnecessary and harmful drugs. Prescribers
are no longer faced with a confusing plethora of
products, which complicates prescribing decisions.
They receive unbiased and scientifically-sound
therapeutic information about defined essential drugs,
and prescribing patterns have correspondingly
improved in quality.
The most important factors accounting for these
achievements have been: compulsory generic-name
prescribing; the publication of the National Formulary,
the Therapeutic Guide, and other norms and
suggestions for the prevention, control, diagnosis and
In Mozambique drugs are nos more like/v to be available at peripheral







1974 1.0 0.11 8.1
1976 3.3 0.30 12.1
1978 7.6 0.65 17.6
1980 8.9 0.71 16.0
1982 12.5 0.96 20.1
treatment of disease; and the creation of a state system
of procurement and distribution. Because medicine
has been nationalised and private practice abolished,
these measures have had nationwide application, with
the positive side-effect that drug-company represent-
atives and promotional maipractices have disappeared
spontaneously.
Although the main reason for the pharmaceutical
policies was to improve the quality of prescribing,
their adoption has also resulted in important
economic gains. Drug prices have decreased, and the
national economy has been defended against the
illegal export of foreign exchange through company
over-invoicing. Health workers have been educated,
not only to prescribe better, but also more
economically: and the two are not incompatible. In
Mozambique drugs are now more likely to be
available at health posts and rural health units than
ever before [Hanlon 1983], and this availability is
better than in many developing countries. It is the
result of the savings made in drug imports, the increase
in the government's pharmaceutical budget, and a
more equitable system of distribution.
It is hoped that Mozambique's experience in the
pharmaceutical sector may be of interest to other
countries, both developing and developed.
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